Objectives: The aim of this study was to assess the in vitro activities of nemonoxacin against Grampositive cocci with various resistance phenotypes.
Introduction
Antimicrobial drug resistance has become a great public health threat worldwide. 1 
concern.
1 Currently available agents with in vitro activities against these resistant pathogens include linezolid and tigecycline. 2 Unfortunately, resistance to these agents occurred soon after their introduction to clinical use.
1,2 Nemonoxacin, a non-fluorinated quinolone, acts by inhibiting bacterial DNA gyrase and retains potent broad-spectrum activities against various bacteria, including Nocardia brasiliensis, and Helicobacter pylori, but has a poor activity against Mycobacterium tuberculosis.
-5
This study aims to investigate the in vitro activity of nemonoxacin against clinically important Gram-positive bacteria with various resistance phenotypes.
Materials and methods
A total of 798 non-duplicate clinical isolates of Gram-positive cocci recovered from various clinical specimens of patients treated at National Taiwan University Hospital from 2005 to 2007 were collected. These included: methicillin-susceptible S. aureus (MSSA; n ¼100); ciprofloxacin-susceptible MRSA (n¼ 50); ciprofloxacinresistant MRSA (n¼ 100); vancomycin-intermediate MRSA (MICs of 4-8 mg/L; n¼ 50); DNS-MRSA (MICs of 2 mg/L; n¼ 5); community-acquired MRSA (CA-MRSA; n ¼101); invasive S. pneumoniae isolates (n¼150); levofloxacin-non-susceptible (MICs of 4-64 mg/L) S. pneumoniae isolates from different parts of Taiwan (n¼30); 6 and enterococci (n¼212), including VRE (n¼112). Isolates of MSSA, MRSA, CA-MRSA and DNS-MRSA were derived from patients with bacteraemia. All enterococcal and VISA isolates were recovered from various clinical specimens. All invasive S. pneumoniae isolates were recovered from normally sterile body sites. The majority of levofloxacin-non-susceptible S. pneumoniae were recovered from respiratory secretions, except for two isolates that were recovered from blood samples. 6 Susceptibilities of MSSA and MRSA to ciprofloxacin, enterococci to vancomycin, and S. pneumoniae isolates to levofloxacin were determined by the routine disc diffusion method. 7 MICs of vancomycin and daptomycin for MRSA isolates were determined using the broth microdilution method. MICs of nemonoxacin for various resistance phenotypes of MRSA and enterococci, and all quinolones for S. pneumoniae were determined using the agar dilution method, and the results were interpreted according to the guidelines established by the CLSI or European Committee on Antimicrobial Susceptibility Testing (EUCAST).
7,8 S. aureus ATCC 29213, Enterococcus faecalis 29212, S. pneumoniae ATCC 49619, and S. aureus Mu50 and Mu3 were used as control strains. 8 S. pneumoniae isolates with levofloxacin MICs of 4 mg/L (defined as non-susceptible by the CLSI criteria and resistant by the EUCAST criteria) were further studied for their mutations in quinolone resistance-determining regions (QRDRs) by PCR and DNA sequence analysis. An isolate with an efflux phenotype was defined as having a 4-fold reduction in the MICs of various quinolones tested in the presence of reserpine (10 mg/L), as described previously. 6 
Results
All MICs of antimicrobial agents tested, except for nemonoxacin, for the five control strains for each run were within the recommended ranges.
7 For nemonoxacin, the MIC was 0.03 -0.06 mg/L for S. aureus ATCC 29213, 0.06 -0.12 mg/L for E. faecalis 29212, 0.03 -0.06 mg/L for S. pneumoniae ATCC 49619 and 0.25-0.05 mg/L for S. aureus Mu50 and Mu3.
All MSSA isolates were susceptible to ciprofloxacin and were inhibited by nemonoxacin at 0.03 mg/L ( Table 1) . The MIC at which 90% of the isolates were inhibited (MIC 90 ) for ciprofloxacin-susceptible MRSA was 0.03 mg/L. For ciprofloxacin-resistant MRSA isolates, the corresponding value was 1 mg/L (88% with MICs of 0.5 mg/L). Among 101 CA-MRSA isolates, 96% were susceptible to levofloxacin and moxifloxacin. Nemonoxacin demonstrated an MIC at which 50% of the isolates Comparative susceptibility results for five quinolones against 150 invasive and 30 levofloxacin-non-susceptible S. pneumoniae isolates are shown in Tables 1 and 2 . For all invasive S. pneumoniae isolates, the activity of nemonoxacin (MIC 90 of 0.06 mg/L) was similar to that of gemifloxacin and much better than that of levofloxacin (MIC 90 of 2 mg/L) and moxifloxacin (MIC 90 of 0.25 mg/L). Nemonoxacin had a 32-to 64-fold higher activity than levofloxacin against levofloxacin-nonsusceptible isolates. For the levofloxacin-non-susceptible isolates, 38.7% and 41.9% of isolates were susceptible to moxifloxacin (1 mg/L) and gemifloxacin (0.12 mg/L) by the CLSI criteria, respectively, and only 6.7% were susceptible to moxifloxacin (0.5 mg/L) by the EUACST criteria. Among these 30 isolates, 23 (76.7%) were inhibited by nemonoxacin at an MIC of 0.5 mg/L, 6 (20.0%) were inhibited by nemonoxacin at an MIC of 1 mg/L and 1 had a high nemonoxacin MIC of 4 mg/L.
Microbiological characteristics of the 30 isolates of levofloxacin-non-susceptible isolates of S. pneumoniae are demonstrated in Table 2 . 6 Most of the isolates with levofloxacin MICs of 4 -8 mg/L possessed amino acid changes involved in resistance, including Ser79 or Asp83 alterations in ParC, or Ser81 or Glu85 alterations in GyrA. Most of the isolates with levofloxacin MICs of 16-64 mg/L possessed both Ser79 and/or Asp83 changes in ParC, and Ser81 or Glu85 changes in GyrA. 6 Among the 30 levofloxacin-non-susceptible isolates, an efflux mechanism contributing to ciprofloxacin, gemifloxacin, levofloxacin and moxifloxacin resistance was detected in 14 isolates, 3 isolates, 1 isolate and 1 isolate, respectively (Table 2) . 6 Among the seven isolates with nemonoxacin MICs of 1 mg/L, five had three or more mutations and two had two mutations in QRDRs. Three of them exhibited the same MICs of other quinolones (levofloxacin, 64 mg/L; moxifloxacin, 4 mg/L; and gemifloxacin, 0.5 mg/L) and identical mutations in parC, gyrA and gyrB. The isolate with a nemonoxacin MIC of 4 mg/L exhibited two mutations in parC (S79F and D83N), one mutation in gyrA (E85K) and an efflux phenotype.
Discussion
In this study, nemonoxacin had potent activity against MSSA (MIC 90 of 0.03 mg/L), ciprofloxacin-susceptible MRSA (MIC 90 of 0.03 mg/L) and CA-MRSA (MIC 90 of 0.06 mg/L), indicating a potential role of this agent in the treatment of infections due to these organisms. 9, 10 However, hospital-acquired and ciprofloxacin-resistant MRSA isolates had significantly higher nemonoxacin MICs (.33-fold higher MIC 90 s) than those of ciprofloxacin-susceptible MRSA and CA-MRSA. These findings were in accordance with those by Adam et al. 10 Furthermore, increasing nemonoxacin MICs (up to 8 mg/L) among VISA (MIC 90 of 2 mg/L) or DNS-MRSA (80% with MICs of 1 mg/L) suggest the limitation of nemonoxacin for treating infections due to these two resistant bacteria.
Nemonoxacin, only currently available in an oral formulation, is rapidly absorbed following oral administration with a half-life of 9 -16 h and the mean plasma protein binding is 16%.
3,9
The free C max is 5.7 mg/L for a single 750 mg dose. 3, 9 The mean 24 h free area under the concentration -time curve (fAUC 0 -24 ) is 46.0 mg . h/L for a single 750 mg dose. 3, 9 For treatment of infections due to Gram-positive cocci, an f AUC 0 -24 to MIC ( f AUC 0 -24 /MIC) value of ,40 (but .30) is generally accepted to predict clinical success and microbiological success, and a value of 100-125 is accepted to not only predict both clinical and microbiological success but also to limit the development of bacterial resistance. 10 In a recent clinical trial on the treatment of community-acquired pneumonia, a 750 mg daily oral dose of nemonoxacin for Gram-positive cocci was used. 3, 9 Accordingly, nemonoxacin displays good ( f AUC 0 -24 /MIC 90 , .100) pharmacokinetics/pharmacodynamics at the 750 mg dose with MSSA (1533), CA-MRSA (766.7) and ciprofloxacin-susceptible MRSA (1533); moderate ( f AUC 0 -24 /MIC 90 , 30 -125) pharmacokinetics/pharmacodynamics at the 750 mg dose with VSE (E. faecalis) (92), ciprofloxacin-resistant MRSA (46) and levofloxacin-nonsusceptible S. pneumoniae (46); and unfavourable ( f AUC 0 -24 / MIC 90 , ,30) pharmacokinetics/pharmacodynamics at the 750 mg dose with VISA (23.0) and other enterococci (,11.5).
Nemonoxacin had apparently greater activity against staphylococci and pneumococci compared with other quinolones. It is possible that nemonoxacin primarily targets gyrase in staphylococci and pneumococci, whereas previously used quinolones target topoisomerase IV and therefore select topoisomerase IV mutants that remain susceptible to nemonoxacin. 3 The reasons why E. faecalis isolates were more susceptible to nemonoxacin, whereas E. faecium isolates were much more resistant, remain unclear. Similarly, why VRE isolates exhibited higher nemonoxacin MICs compared with those for VSE isolates needs further investigation.
In conclusion, our findings point to a potentially useful place for nemonoxacin in the treatment of infections caused by resistant Gram-positive cocci, except for VISA, vancomycin-susceptible E. faecium and VRE. However, increases in MICs of nemonoxacin did occur among isolates non-susceptible to other quinolones. Further clinical studies on the treatment of infections due to these resistant organisms are needed to elucidate its clinical efficacy.
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